

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5849420

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FEDERICO GROSSI	09/04/2019
PASCAL DESCHATELETS	09/06/2019
CEDRIC FRANCOIS	09/06/2019
CAROLINA VEGA	09/05/2019
RECEIVING PARTY DATA	
Name:	APELLIS PHARMACEUTICALS, INC.
Street Address:	6400 WESTWIND WAY
Internal Address:	SUITE A
City:	CRESTWOOD
State/Country:	KENTUCKY
Postal Code:	40014
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16500994
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6172485000
Email:	patentdocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2008575-0384
NAME OF SUBMITTER:	SOWMYA SUBRAMANIAN, PHD
SIGNATURE:	/Sowmya Subramanian/
DATE SIGNED:	12/04/2019
Total Attachments: 9	
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page1.tif	

source=2008575-0384 Joint Assignment (Inventors to Apellis)#page2.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page3.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page4.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page5.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page6.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page7.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page8.tif
source=2008575-0384 Joint Assignment (Inventors to Apellis)#page9.tif

COMBINED JOINT ASSIGNMENT & DECLARATION**A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Federico Grossi	Newton, Massachusetts
2. Pascal Deschatelets	Prospect, Kentucky
3. Cedric Francois	Prospect, Kentucky
4. Carolina Vega	Berkeley, California

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS; and

☐ prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on _____; and

☒ identified by International Patent Application No. PCT/US18/26753
filed on Monday, April 9, 2018; and

☒ and is also aware of the following priority applications:

Serial No.	Filed
62/485343	April 13, 2017
62/483295	April 7, 2017

WHEREAS, **Apellis Pharmaceuticals, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **6400 Westwind Way Suite A, Crestwood, Kentucky 40014**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout

the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said

application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS; and

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application Serial No. _____
filed in the United States Patent and Trademark Office on _____; or

☒ identified by International Patent Application No. PCT/US18/26753
filed on Monday, April 9, 2018.

The above-identified application was made or authorized to be made by us.

We believe that we are each an original joint inventor of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Signature: _____

Federico Grossi

Date: _____

9/4/19

Witness Signature: _____

Cylin Farhan

Witness Name (printed): _____

Cheryl van Farchmin

Witness Signature: _____

Susan Palmer

Witness Name (printed): _____

Susan Palmer

Signature: _____

Pascal Deschatelets

Date: _____

Sep 6, 2019

Witness Signature: _____

Erin Johnson

Witness Name (printed): _____

Erin Johnson

Witness Signature: _____

Karen Zello

Witness Name (printed): _____

Karen Zello

Signature: _____

Cedric Francois

Date: September 6, 2019

Witness Signature: _____

Witness Name (printed): _____

Tyler Curran

Tyler Curran

Witness Signature: _____

Witness Name (printed): _____

E. Johnson

Erin Johnson

Signature: _____

Carolina Vega

Date: 5 Sept 2019

Witness Signature: _____

Karen Zullo

Witness Name (printed): _____

Karen Zullo

Witness Signature: _____

E. Johnson

Witness Name (printed): _____

Erin Johnson

The undersigned (whose title is supplied below) is authorized to act on behalf of
Apellis Pharmaceuticals, Inc..

Signature: _____

Date: _____

Name (printed): _____

Title (printed): _____

[Handwritten Signature]

August 28, 2019

David O. Watson

Secretary